Oral Anabolic Steroids Compared: Turinabol, Anavar, Dianabol, Anadrol, Halotestin, Proviron, and Superdrol

Oral anabolic steroids get lumped together constantly, but the seven compounds covered here have wildly different origin stories, wildly different relationships to legitimate medicine, and — as a result — wildly different risk-benefit profiles. One shares its mechanism (and its liver risk) with the others through a common chemical modification; the details of where each one came from and how it's actually been studied explain most of the practical differences between them. The Shared Mechanism Behind Most of These Nearly all oral anabolic steroids (Proviron is the one meaningful exception here) are 17-alpha-alkylated — a structural modification that protects the molecule from being destroyed on its first pass through the liver, which is what makes oral administration and reasonable bioavailability possible in the first place. This is the same first-pass metabolism issue covered in our articles on TRT delivery routes and HGH — and it's precisely why oral steroids carry meaningfully more hepatotoxicity risk than injectable ones: the modification that makes them work orally is also what stresses the liver. Turinabol: Born From a State Doping Program, Not Medicine Turinabol (chlorodehydromethyltestosterone) is the one compound on this list with essentially no legitimate medical origin story at all. Developed by the East German pharmaceutical company Jenapharm, it became the centerpiece of one of the most documented state-sponsored doping programs in history. According to PubMed, declassified East German government documents revealed a secret program (formally "State Plan 14.25") in which thousands of athletes — including minors of both sexes — were administered androgenic steroids annually from 1966 onward, with women and adolescent girls specifically targeted because androgens proved particularly effective for their sports performance, and documented side effects sometimes requiring surgical or medical intervention ([Franke & Berendonk, Clinical Chemistry, 1997, PMID: 9216474](https://pubmed.ncbi.nlm.nih.gov/9216474/)). Turinabol was never developed with a genuine therapeutic target population in mind — it exists almost entirely because of this program, which makes its risk-benefit calculation different in kind from every other compound here: there's no legitimate medical benefit column to weigh against the risk at all. Anavar (Oxandrolone): The One With a Real, Ongoing Medical Career Anavar is the clear outlier on this list in the best possible way — it remains FDA-approved and is actually prescribed today, not just historically studied. According to PubMed, a randomized controlled trial in severely burned children (more than 40% total body surface area) found that oxandrolone combined with an exercise program produced significantly greater improvements in lean body mass and muscle strength than either intervention alone ([Przkora, Herndon & Suman, Pediatrics, 2006, PMID: 17130281](https://doi.org/10.1542/peds.2006-1548)). Anavar is also used for weight gain following surgery or chronic infection, for alcoholic hepatitis, and for growth promotion in girls with Turner syndrome. It's C17-alkylated like most of this list, but its hepatotoxicity is generally considered comparatively milder than the others here, and its androgenic activity is comparatively mild as well — the combination of a genuine, ongoing legitimate medical use and a relatively more favorable side effect profile makes it the strongest risk-benefit case of anything on this list, when used at doses within its actual approved medical range. Dianabol (Methandrostenolone): The Cold War Original Dianabol has perhaps the most culturally significant origin story of any anabolic steroid — developed by Ciba with physician Dr. John Ziegler, who worked with U.S. Olympic weightlifting teams and is widely credited as introducing anabolic steroids into American athletics specifically as a response to Soviet athletic dominance in the 1950s. It was discontinued as a human pharmaceutical by Ciba in the early 1980s and has had no legitimate manufacturer since. Dianabol aromatizes significantly to estrogen, producing pronounced water retention and a comparatively high gynecomastia risk relative to several compounds on this list, on top of the hepatotoxicity shared with other C17-alkylated orals. It has essentially no modern legitimate medical use to weigh against that risk profile — its entire relevance today is historical and performance-related. Anadrol (Oxymetholone): Still a Real Anemia Treatment Like Anavar, Anadrol has retained genuine, ongoing FDA-approved medical relevance — specifically for anemias caused by bone marrow failure, including aplastic anemia and Fanconi anemia. According to PubMed, research using a Fanconi anemia mouse model found that chronic oxymetholone treatment significantly improved bone marrow cellularity and blood cell counts, working partly by stimulating proliferation of blood-forming stem cells — directly relevant mechanistic evidence for why it remains a real treatment option in this specific disease context ([Zhang et al., Stem Cell Reports, 2014, PMID: 25434823](https://doi.org/10.1016/j.stemcr.2014.10.014)). Despite this legitimate use, Anadrol carries a reputation as one of the more hepatotoxic compounds on this list, along with pronounced negative effects on cholesterol and a strong tendency toward water retention despite not aromatizing through the typical estrogen pathway — a real medical use, but a correspondingly serious side effect profile even within its approved context. Halotestin (Fluoxymesterone): A Genuine Trial, a Genuine Disappointment Halotestin has real clinical trial history behind it, and that history is exactly why it's fallen out of use. According to PubMed, a randomized controlled trial in postmenopausal women with metastatic breast cancer compared tamoxifen alone against tamoxifen combined with fluoxymesterone. The combination showed a modestly higher response rate (53% vs. 42%) and longer time to disease progression, but the researchers' own conclusion was direct: the advantage wasn't large enough to justify routine use, given the lack of a survival benefit and the greater androgenic toxicity observed with the combination ([Ingle et al., Journal of Clinical Oncology, 1988, PMID: 3284975](https://doi.org/10.1200/JCO.1988.6.5.825)). This is a genuinely useful, rare thing in this list: a real trial demonstrating exactly the poor risk-benefit ratio the compound is now known for, in the researchers' own words. Halotestin carries an extremely high androgenic rating relative to its anabolic effect — among the least favorable ratios of any compound in this article — and is generally regarded in bodybuilding contexts as useful mainly for strength and aggression rather than mass, at a disproportionate cost in side effects. Proviron (Mesterolone): Not Really a Muscle-Builder At All Proviron is a genuine outlier on this list mechanistically: it's not significantly anabolic, and it isn't C17-alkylated, meaning it doesn't carry the same hepatotoxicity profile as the rest of this article. It was developed for male hypogonadism and studied specifically for male infertility. According to PubMed, a Cochrane systematic review of 11 trials involving 930 patients found that mesterolone (alongside testosterone undecanoate) used as a "stimulatory" fertility therapy showed little effect on hormonal outcomes or sperm parameters, with no significant difference in pregnancy rates compared to placebo — the review's direct conclusion was that there isn't enough evidence to support androgen therapy for male subfertility ([Vandekerckhove et al., Cochrane Database of Systematic Reviews, 2007, PMID: 17636603](https://doi.org/10.1002/14651858.CD000150)). In bodybuilding use, Proviron is included in regimens not for muscle building but for its anti-estrogenic, SHBG-binding properties (freeing up other circulating androgens) and libido effects — a fundamentally different role than every other compound on this list. Superdrol (Methasterone): The Supplement-Era Cautionary Tale Superdrol has the most recent and, in some ways, most avoidable origin story here. It was briefly sold openly as an unregulated "prohormone" dietary supplement in the mid-2000s, exploiting a regulatory gap before the Anabolic Steroid Control Act amendments explicitly scheduled it as a controlled substance. It never had any legitimate pharmaceutical development or approved medical use at any point. According to PubMed, a review of liver injury associated with sporting activities specifically identifies bodybuilding supplements containing anabolic steroids — exactly the category Superdrol was sold under during this period — as capable of producing adverse hepatic effects ranging from mild enzyme elevations to severe cholestatic hepatitis with prolonged jaundice ([Hassan & Fontana, Seminars in Liver Disease, 2018, PMID: 30357773](https://doi.org/10.1055/s-0038-1670656)). Superdrol is widely regarded, even within bodybuilding circles, as carrying an unusually severe hepatotoxicity profile relative to its era of being marketed as an over-the-counter "supplement" rather than a recognized pharmaceutical — a genuinely dangerous mismatch between how it was sold and what it actually was. Putting the Risk-Benefit Picture Together Ranking these roughly by legitimate medical benefit relative to documented risk: Anavar has the strongest case, with genuine ongoing FDA-approved use and a comparatively milder side effect profile. Anadrol follows, with real ongoing medical use (bone marrow failure anemias) but a more severe hepatotoxicity and lipid profile even within that legitimate context. Halotestin has real trial data showing it works for its intended medical purpose, but that same trial data is the strongest evidence for why its side effect burden doesn't justify its modest benefit. Proviron is a different case entirely — genuinely lower hepatotoxicity due to its different chemical structure, but essentially unproven for its original medical indication. Dianabol, Turinabol, and Superdrol sit at the bottom of this ranking for the same underlying reason: no meaningful ongoing legitimate medical benefit to weigh against real, documented hepatotoxicity risk — Turinabol and Superdrol in particular never had a legitimate medical purpose to begin with, existing specifically because of a doping program and a supplement-marketing loophole, respectively. The Bottom Line These seven oral compounds aren't a single category with interchangeable risk profiles — they range from Anavar, a genuinely still-prescribed pediatric and clinical medication with a comparatively favorable safety record, to Turinabol and Superdrol, compounds whose entire existence traces back to a state doping program and a regulatory loophole rather than any legitimate medical development process. All of them carry real, documented hepatotoxicity risk from the same C17-alkylation mechanism (Proviron excepted), and understanding where each one actually came from — a Cold War lab, a burn unit, a bone marrow clinic, a breast cancer trial, or a supplement shelf — tells you most of what you need to know about how seriously to weigh its risk against whatever benefit it's actually being used for.